Present status of treatment in peritoneal metastasis of gastric cancer
10.3760/cma.j.issn.1671-0274.2015.02.025
- VernacularTitle:胃癌腹膜转移治疗现状
- Author:
Zhefang WANG
1
;
Li CHEN
Author Information
1. 浙江大学医学院附属第二医院普通外科
- Keywords:
Stomach neoplasms;
Peritoneal metastasis;
Cytoreductive surgery;
Intra-peritoneal chemotherapy;
Molecular targeted therapy
- From:
Chinese Journal of Gastrointestinal Surgery
2015;(2):194-197
- CountryChina
- Language:Chinese
-
Abstract:
Peritoneal metastasis is considered as the end stage of gastric cancer, which is a fatal malignancy without the chance of surgery. No standard regimens are recommended. Routine treatments can not improve the survival of these patients, while multidisciplinary treatments may probably be promising. Aggressive treatments such as cytoreductive surgery, intra-peritoneal chemotherapy and bidirectional chemotherapy are applied to clinical management in recent years. Furthermore, molecular targeted therapy and immune therapy are developed and making individualized treatment possible. Individualized treatment according to clinical characteristics and expression of biomarkers will be the future of peritoneal metastasis of gastric cancer.
